Amgen 1st-qtr results show flat group revenues and EPS downturn
US biotech giant Amgen (Nasdaq: AMGN) late yesterday announced financial results for the first quarter of 2019, noting that total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018, largely in line with consensus analysts’ estimates of $5.55 billion.
On a generally accepted accounting principles (GAAP) basis, earnings per share (EPS) decreased 2% to $3.18 driven by higher total operating expenses, offset partially by lower weighted-average shares outstanding.
Non-GAAP EPS increased 3% to $3.56 benefited by lower weighted-average shares outstanding, topping the view of analysts polled by Zacks Investment Research by 11 cents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze